CELLUMEN, INC.

PITTSBURGH, PA · Founded 2004 · Software · Still private

ELISA kits and antibodies for research and diagnostics

Claim this profile

Follows are private to you and power your alerts

Updated · cellumen.com

Sector
Software
Headquarters
PITTSBURGH, PA
Founded
2004
Latest Form D
$248K, Mar 2010
Total capital
$1.6M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$1.6M
3 Form D · last Mar 2010
200 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
7 pending

Capital timeline

20092010FEDERAL ↑EQUITY ↓Cumulative $1.6M1st Form D$622K2nd Form D$694K3rd Form D$248K
20092010FEDERAL ↑EQUITY ↓Cumulative $1.6M1st Form D$622K3rd Form D$248K

Latest events

  • Private capital raisedForm D · SEC · 3rd filing$248K
  • Private capital raisedForm D · SEC · 2nd filing$694K
  • Private capital raisedForm D · SEC · 1st filing$622K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • Albert L. GoughExecutive OfficerNamed in SEC Form D filings
  • Dean L MillerDirectorNamed in SEC Form D filings
  • Donald P. TaylorExecutive OfficerNamed in SEC Form D filings
  • D. Lansing TaylorExecutive Officer, DirectorNamed in SEC Form D filings
  • Franklyn L PrendergastDirectorNamed in SEC Form D filings
  • Gregory L. FinertyExecutive OfficerNamed in SEC Form D filings
Show all 12 people
  • Jack L ReynoldsDirectorNamed in SEC Form D filings
  • James L. DatinDirectorNamed in SEC Form D filings
  • LeRoy L MetzDirectorNamed in SEC Form D filings
  • Matthew L MalenfantDirectorNamed in SEC Form D filings
  • Patricia A. JohnstonExecutive OfficerNamed in SEC Form D filings
  • Rosemary L MazanetDirectorNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 7
  • PendingMethod For Predicting Biological Systems Responses In HepatocytesUSPTOApplication PCTUS2008008105
  • PendingMethods For Detecting Molecular Interactions Within Cells Using Combination Of Inducible Promoters And BiosensorsUSPTOApplication PCTUS2008003401
  • PendingProtein-protein Interaction Biosensors And Methods Of Use ThereofUSPTOApplication PCTUS2007023678
Show all 7 patent records
  • Method For Predicting Biological Systems Responses In HepatocytesApplication PCTUS2008008105Pending
  • Methods For Detecting Molecular Interactions Within Cells Using Combination Of Inducible Promoters And BiosensorsApplication PCTUS2008003401Pending
  • Protein-protein Interaction Biosensors And Methods Of Use ThereofApplication PCTUS2007023678Pending
  • Method For Modeling A DiseaseApplication PCTUS2007012406Pending
  • Method For Automated Tissue AnalysisApplication PCTUS2007011865Pending
  • Method For Predicting Biological Systems ResponsesApplication PCTUS2007001217Pending
  • Methods For The Detection Of Molecular Interactions Within CellsApplication PCTUS2005027919Pending
  • IIOT-OXYS, Inc.Similar federal contract value in Software · null in contracts
  • Augmodo Inc.Similar federal contract value in Software · null in contracts
  • VOLT Analytics, LLCSimilar federal contract value in Software · null in contracts
  • Transform, Inc.Similar federal contract value in Software · null in contracts
  • VIDEOMINING CORPSimilar federal contract value in Software · null in contracts
  • RingCentral IncSimilar federal contract value in Software · null in contracts

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .